Novavax Company Profile (NASDAQ:NVAX)

About Novavax (NVAX)

Novavax logoNovavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: NVAX
  • CUSIP: 67000210
Key Metrics:
  • Previous Close: $0.81
  • 50 Day Moving Average: $1.1814
  • 200 Day Moving Average: $1.3624
  • 52-Week Range: $0.73 - $8.49
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.27
  • P/E Growth: 0.0000
  • Market Cap: $220.68M
  • Outstanding Shares: 271,200,000
  • Beta: 1.72
  • Net Margins: -1,908.41%
  • Return on Equity: -189.14%
  • Return on Assets: -61.47%
  • Debt-to-Equity Ratio: 6.35%
  • Current Ratio: 4.68%
  • Quick Ratio: 4.68%

Analyst Ratings

Consensus Ratings for Novavax (NASDAQ:NVAX) (?)
Ratings Breakdown: 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.22)
Consensus Price Target: $5.71 (601.58% upside)

Analysts' Ratings History for Novavax (NASDAQ:NVAX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/1/2017Cantor FitzgeraldReiterated RatingNeutral$2.00N/AView Rating Details
3/1/2017Ladenburg Thalmann Financial ServicesReiterated RatingNeutralN/AView Rating Details
2/28/2017Chardan CapitalReiterated RatingHold$1.50N/AView Rating Details
1/18/2017FBR & CoReiterated RatingOutperform$12.00N/AView Rating Details
11/11/2016WedbushReiterated RatingNeutral$2.00 -> $1.50N/AView Rating Details
11/10/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
9/16/2016S&P Equity ResearchLower Price Target$1.44 -> $1.17N/AView Rating Details
9/16/2016Citigroup IncDowngradeBuy -> Neutral$12.00 -> $1.50N/AView Rating Details
9/16/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$14.00 -> $1.00N/AView Rating Details
8/29/2016GuggenheimReiterated RatingBuy$25.00N/AView Rating Details
(Data available from 4/24/2015 forward)


Earnings History for Novavax (NASDAQ:NVAX)
Earnings by Quarter for Novavax (NASDAQ:NVAX)
Earnings History by Quarter for Novavax (NASDAQ:NVAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017Q416($0.23)($0.21)$5.45 million$5.40 millionViewListenView Earnings Details
11/9/2016Q316($0.26)($0.24)$4.02 million$3.20 millionViewListenView Earnings Details
8/9/2016Q216($0.25)($0.29)$8.03 million$2.50 millionViewListenView Earnings Details
5/4/2016Q1($0.27)($0.29)$10.39 million$4.20 millionViewListenView Earnings Details
2/29/2016Q415($0.14)($0.29)$8.07 million$5.90 millionViewListenView Earnings Details
11/9/2015Q315($0.09)($0.12)$10.59 million$6.50 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)($0.08)$9.90 million$14.00 millionViewListenView Earnings Details
5/7/2015Q115($0.11)($0.10)$9.70 million$9.88 millionViewN/AView Earnings Details
2/26/2015Q4 14($0.08)($0.13)$9.60 million$6.70 millionViewN/AView Earnings Details
11/5/2014Q314($0.07)($0.08)$9.20 million$8.20 millionViewN/AView Earnings Details
8/6/2014Q214($0.07)($0.08)$8.74 million$8.26 millionViewN/AView Earnings Details
5/7/2014Q114($0.07)($0.07)$3.80 million$7.50 millionViewN/AView Earnings Details
3/10/2014Q413($0.08)($0.07)$6.22 million$8.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.06)($0.09)$4.56 million$4.80 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.06)($0.08)$4.45 million$3.50 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.06)($0.07)$5.54 million$3.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012($0.04)($0.06)$5.85 million$4.57 millionViewN/AView Earnings Details
11/2/2012Q312($0.05)($0.05)$7.59 million$5.80 millionViewN/AView Earnings Details
8/3/2012($0.07)($0.05)ViewN/AView Earnings Details
5/4/2012($0.04)($0.06)ViewN/AView Earnings Details
3/9/2012($0.04)($0.03)ViewN/AView Earnings Details
11/4/2011($0.06)($0.03)ViewN/AView Earnings Details
8/5/2011($0.08)($0.04)ViewN/AView Earnings Details
5/9/2011($0.07)($0.07)ViewN/AView Earnings Details
3/28/2011($0.09)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Novavax (NASDAQ:NVAX)
2017 EPS Consensus Estimate: ($0.64)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.19)($0.17)($0.18)
Q2 20172($0.16)($0.15)($0.16)
Q3 20172($0.17)($0.15)($0.16)
Q4 20172($0.15)($0.14)($0.15)
(Data provided by Zacks Investment Research)


Dividend History for Novavax (NASDAQ:NVAX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Novavax (NASDAQ:NVAX)
Insider Ownership Percentage: 3.50%
Institutional Ownership Percentage: 60.36%
Insider Trades by Quarter for Novavax (NASDAQ:NVAX)
Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)
Insider Trades by Quarter for Novavax (NASDAQ:NVAX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/31/2017Barclay A. PhillipsCFOBuy1,633$1.12$1,828.96View SEC Filing  
1/31/2017John A. Herrmann IIISVPBuy4,960$1.12$5,555.20View SEC Filing  
12/7/2016Gregory M GlennInsiderBuy1,000$1.45$1,450.00View SEC Filing  
9/22/2016John TrizzinoSVPBuy46,000$2.17$99,820.00View SEC Filing  
9/21/2016Gregory M GlennInsiderBuy1,000$1.65$1,650.00View SEC Filing  
9/21/2016Michael A Mcmanus JrDirectorBuy30,000$1.61$48,300.00View SEC Filing  
9/20/2016Gail BoudreauxDirectorBuy100,000$1.45$145,000.00View SEC Filing  
7/31/2016Barclay A. PhillipsCFOBuy422$4.29$1,810.38View SEC Filing  
6/6/2016Gary C EvansDirectorSell18,998$6.50$123,487.00View SEC Filing  
5/24/2016Gary C EvansDirectorSell50,000$5.41$270,500.00View SEC Filing  
3/31/2016Stanley C ErckCEOSell424,778$5.19$2,204,597.82View SEC Filing  
1/31/2016Barclay A. PhillipsCFOBuy405$4.38$1,773.90View SEC Filing  
1/31/2016Gregory M. GlennSVPBuy2,369$4.38$10,376.22View SEC Filing  
1/31/2016Stanley C. ErckCEOBuy2,072$4.38$9,075.36View SEC Filing  
12/16/2015John A Herrmann IIISVPSell27,945$8.64$241,444.80View SEC Filing  
8/24/2015Gary C EvansDirectorSell20,000$11.24$224,800.00View SEC Filing  
8/20/2015Barclay A. PhillipsCFOSell28,656$13.06$374,247.36View SEC Filing  
8/18/2015Gregory M. GlennSVPSell15,000$13.52$202,800.00View SEC Filing  
8/13/2015Gary C EvansDirectorSell6,002$13.56$81,387.12View SEC Filing  
6/18/2015James F YoungDirectorSell50,000$9.47$473,500.00View SEC Filing  
6/17/2015Rajiv I ModiDirectorSell433,053$9.01$3,901,807.53View SEC Filing  
6/11/2015Rajiv I ModiDirectorSell11,185$9.00$100,665.00View SEC Filing  
6/10/2015Rajiv I ModiDirectorSell551,081$8.97$4,943,196.57View SEC Filing  
6/9/2015Rajiv I ModiDirectorSell47,531$8.93$424,451.83View SEC Filing  
6/8/2015Rajiv I ModiDirectorSell206,175$8.93$1,841,142.75View SEC Filing  
6/4/2015Rajiv I ModiDirectorSell504,681$8.92$4,501,754.52View SEC Filing  
6/1/2015Rajiv I ModiDirectorSell3,500,000$8.74$30,590,000.00View SEC Filing  
1/31/2015Barclay A PhillipsCFOBuy8,388$2.28$19,124.64View SEC Filing  
1/31/2015John TrizzinoSVPBuy6,611$3.63$23,997.93View SEC Filing  
1/31/2015Stanley C ErckCEOBuy6,122$2.28$13,958.16View SEC Filing  
12/16/2014Gary C EvansDirectorSell46,701$5.72$267,129.72View SEC Filing  
12/12/2014Gary C EvansDirectorSell30,000$5.77$173,100.00View SEC Filing  
11/20/2014Rajiv I ModiDirectorSell518,889$5.02$2,604,822.78View SEC Filing  
11/18/2014Rajiv I ModiDirectorSell1,481,111$5.00$7,405,555.00View SEC Filing  
10/3/2014Barclay A PhillipsCFOBuy5,000$4.11$20,550.00View SEC Filing  
10/3/2014Timothy Jon HahnSVPBuy2,500$4.05$10,125.00View SEC Filing  
9/26/2014Gregory M GlennSVPSell16,809$4.16$69,925.44View SEC Filing  
9/25/2014Timothy Jon HahnSVPBuy9,000$4.17$37,530.00View SEC Filing  
7/31/2014Barclay A PhillipsCFOBuy8,788$2.28$20,036.64View SEC Filing  
7/31/2014Russell P WilsonSVPBuy4,989$2.28$11,374.92View SEC Filing  
7/31/2014Stanley C ErckCEOBuy6,788$2.28$15,476.64View SEC Filing  
6/17/2014John TrizzinoSVPBuy5,500$4.51$24,805.00View SEC Filing  
6/16/2014John TrizzinoSVPBuy16,500$4.51$74,415.00View SEC Filing  
3/25/2014Barclay PhillipsCFOBuy5,000$4.25$21,250.00View SEC Filing  
3/25/2014Richard DouglasDirectorBuy50,000$4.33$216,500.00View SEC Filing  
3/25/2014Stanley ErckCEOBuy10,000$4.27$42,700.00View SEC Filing  
3/21/2014Pharmaceuticals Ltd Cadilamajor shareholderSell3,000,000$4.95$14,850,000.00View SEC Filing  
1/31/2014Barclay PhillipsCFOBuy9,868$2.29$22,597.72View SEC Filing  
1/31/2014Stanley ErckCEOBuy11,868$2.29$27,177.72View SEC Filing  
1/31/2014Timothy Jon HahnSVPBuy9,416$2.29$21,562.64View SEC Filing  
6/12/2013Richard DouglasDirectorBuy50,000$1.90$95,000.00View SEC Filing  
6/10/2013Timothy Jon HahnSVPBuy21,000$1.88$39,480.00View SEC Filing  
6/7/2013Gregory M GlennInsiderBuy2,000$1.92$3,840.00View SEC Filing  
6/6/2013James F YoungDirectorBuy100,000$1.91$191,000.00View SEC Filing  
3/11/2013James F YoungDirectorBuy100,000$2.03$203,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Novavax (NASDAQ:NVAX)
Latest Headlines for Novavax (NASDAQ:NVAX)
DateHeadline logoETFs with exposure to Novavax, Inc. : April 19, 2017 - April 19 at 6:58 PM logoNovavax, Inc. (NVAX) Given Consensus Rating of "Hold" by Brokerages - April 17 at 6:58 PM logoNovavax (NVAX) Getting Somewhat Negative Press Coverage, Report Shows - April 15 at 1:21 PM logoNovavax, Inc. (NVAX) Sees Large Decline in Short Interest - April 14 at 7:24 AM logoBiotech Movers Trading Positive Ahead of Market's Open - April 11 at 10:52 AM logoETFs with exposure to Novavax, Inc. : April 7, 2017 - April 7 at 7:20 PM logoImplied Volatility Surging for Novavax (NVAX) Stock Options - April 7 at 11:35 AM logoToday's Research Reports on Biotech Stocks to Watch: Sarepta Therapeutics and Novavax - April 7 at 11:35 AM logoDown 12.5%: Is Novavax Stock Too Cheap To Ignore? - April 7 at 9:51 AM logoThe Waiting Game Crushed Novavax, Inc. in March, Sending Shares Down 15% - April 5 at 11:16 AM logoVBI Vaccines Is An Alternative To The Agenus Inc. Failure - March 28 at 10:02 AM logoNovavax, Inc. (NVAX) Receives Consensus Rating of "Hold" from Brokerages - March 22 at 11:56 AM logoTrade Volume Can Speak a Lot About Momentum of a Stock - March 16 at 7:41 PM logoBiotech Stocks Under Scanner -- Gilead Sciences, Exelixis, Mast Therapeutics, and Novavax - March 14 at 10:36 AM logoChardan Capital Reaffirms Hold Rating for Novavax, Inc. (NVAX) - March 12 at 4:30 PM logoThese Popular Stocks Could Prove Toxic for Your Portfolio - March 9 at 8:15 AM logoWhy Novavax's Shares Marched Higher in February - March 6 at 11:15 AM logoNOVAVAX INC Financials - March 3 at 6:56 PM logoIs There Still A Path Forward For The Novovax RSV Vaccine? - March 1 at 10:32 AM logoNOVAVAX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 1 at 10:31 AM logoHere's Why Novavax, Inc.'s Share Price Went Down the Drain - February 28 at 6:51 PM logoNovavax, Inc. (NVAX) - February 28 at 10:31 AM logoNovavax Stock Spikes on Q4 Results (NVAX) - February 28 at 10:31 AM logo4:08 pm Novavax beats by $0.02, reports revs in-line - February 28 at 10:31 AM logoNovavax Stock Spikes on Q4 Results - February 28 at 10:31 AM logoNovavax: 'We still expect to enjoy the advantage of being the first RSV vaccine' - February 28 at 10:31 AM logoEARNINGS SUMMARY: Details of Novavax Inc. Q4 Earnings Report - February 27 at 5:48 PM logoQ4 2016 Novavax Inc Earnings Release - After Market Close - February 27 at 5:48 PM logoNovavax Reports Fourth Quarter and Year-End 2016 Financial Results - February 27 at 5:48 PM logoNOVAVAX INC Files SEC form 10-K, Annual Report - February 27 at 5:48 PM logoNOVAVAX INC - February 22 at 8:57 AM logoNovavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 ... - February 20 at 6:14 PM logoNovavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results on February … - February 20 at 6:14 PM logoNovavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results on February 27, 2017 - February 20 at 4:43 PM logoBetter Buy: Novavax, Inc. vs. Inovio Pharmaceuticals - February 16 at 11:16 AM


Frequently Asked Questions for Novavax (NASDAQ:NVAX)

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings results on Monday, February, 27th. The company reported ($0.21) EPS for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.02. The company had revenue of $5.40 million for the quarter, compared to analysts' expectations of $5.45 million. Novavax had a negative net margin of 1,908.41% and a negative return on equity of 189.14%. Novavax's revenue was down 7.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.29) EPS.

When will Novavax make its next earnings announcement?

Novavax is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.

Where is Novavax's stock going? Where will Novavax's stock price be in 2017?

9 brokerages have issued 12 month price targets for Novavax's stock. Their predictions range from $1.00 to $25.00. On average, they expect Novavax's share price to reach $5.71 in the next twelve months.

What are analysts saying about Novavax stock?

Here are some recent quotes from research analysts about Novavax stock:

  • 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (3/3/2017)
  • 2. Chardan Capital analysts commented, "The company is at a pre-commercialization stage, although it does recognize revenue from research and development collaborations. Reported revenue in Q4 was $5.4M, which was inline with consensus." (2/28/2017)
  • 3. Cantor Fitzgerald analysts commented, "RSV maternal vaccination likely primary value driver in 2017. We believe investors will be keenly focused on the RSV vaccine when used in the context of maternal vaccination, particularly given the failure of the elderly subject RSV pivotal trial late last year. Clinical data suggest that the vaccine is immunogenic in pregnant women and that anti-RS F protein antibodies are efficiently transferred across the placenta to the fetus." (1/12/2017)
  • 4. Piper Jaffray Companies analysts commented, "So, Now What?" (9/16/2016)

Are investors shorting Novavax?

Novavax saw a decrease in short interest in the month of March. As of March 31st, there was short interest totalling 59,358,979 shares, a decrease of 10.3% from the March 15th total of 66,200,808 shares. Based on an average daily trading volume, of 4,883,977 shares, the short-interest ratio is presently 12.2 days. Approximately 22.2% of the company's shares are sold short.

Who owns Novavax stock?

Novavax's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Creative Planning (0.12%) and Nationwide Fund Advisors (0.06%). Company insiders that own Novavax stock include Barclay A Phillips, Gail Boudreaux, Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rajiv I Modi and Stanley C Erck.

Who sold Novavax stock? Who is selling Novavax stock?

Novavax's stock was sold by a variety of institutional investors in the last quarter, including Creative Planning and Nationwide Fund Advisors.

How do I buy Novavax stock?

Shares of Novavax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Novavax stock cost?

One share of Novavax stock can currently be purchased for approximately $0.81.

Novavax (NVAX) Chart for Monday, April, 24, 2017

This page was last updated on 4/24/2017 by Staff